{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:29:16Z","timestamp":1779107356350,"version":"3.51.4"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            There is currently no standardized serum bactericidal antibody (SBA) assay for evaluating immune responses to meningococcal outer membrane vesicle or protein vaccines. Four laboratories, Manchester Health Protection Agency (MC HPA), New Zealand Institute of Environmental Science and Research Limited (NZ ESR), Norwegian Institute of Public Health (NIPH), and Chiron Vaccines (Chiron), measured SBA titers in the same panel of human sera (\n            <jats:italic>n<\/jats:italic>\n            = 76) from laboratory staff (\n            <jats:italic>n<\/jats:italic>\n            = 21) vaccinated with MenBvac. Blood samples were collected prevaccination, prior to each of the three doses of MenBvac given at 6-week intervals, and 6 weeks following the third dose. Initial results showed a number of discrepancies in results between the four participating laboratories. The greatest effect on titers appeared to be due to differences among laboratories in the maintenance of the meningococcal serogroup B test strain, 44\/76-SL. A repeat study was conducted using the same frozen isolate (meningococcal serogroup B test strain 44\/76-SL), freshly distributed to all four laboratories. Using SBA titers from the tilt method for all samples, and using MC HPA as the comparator, the results were as follows for NZ ESR, NIPH, and Chiron, respectively, using log\n            <jats:sub>10<\/jats:sub>\n            titers: correlation coefficients (\n            <jats:italic>r<\/jats:italic>\n            ) were 0.966, 0.967, and 0.936; intercepts were 0.08, 0.15, and 0.17; and slopes were 0.930, 0.851, and 0.891. In both prevaccination and postvaccination samples from 15 subjects assayed by all four laboratories, similar increases in SBA (fourfold or greater) were observed (for 11, 11, 9, and 9 subjects for MC HPA, NZ ESR, NIPH, and Chiron, respectively), and similar percentages of subjects with SBA titers of \u22654 prevaccination and 6 weeks following each dose were found. The SBA assay has been harmonized between the four different laboratories with good agreement on seroconversion rates,\n            <jats:italic>n<\/jats:italic>\n            -fold changes in titers, and percentages of subjects with SBA titers of \u22654.\n          <\/jats:p>","DOI":"10.1128\/cdli.12.8.970-976.2005","type":"journal-article","created":{"date-parts":[[2005,8,5]],"date-time":"2005-08-05T22:13:00Z","timestamp":1123279980000},"page":"970-976","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44\/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine"],"prefix":"10.1128","volume":"12","author":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg S.","family":"Aaberge","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George F.","family":"Santos","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Lynn","family":"Eudey","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Glennie","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Arne","family":"H\u00f8iby","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einar","family":"Rosenqvist","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Martin","sequence":"additional","affiliation":[{"name":"Meningococcal Reference Unit, HPA North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, NO-0403 Oslo, Norway"},{"name":"Chiron Vaccines, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Biostatistics, 4560 Horton Street, Emeryville, California 94608-2916"},{"name":"Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"780","volume":"10","year":"2003","unstructured":"Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10:780-786.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. H\u00f8iby, J. K. Gr\u00f8nnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. N\u00f8kleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Fr\u00f8holm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","volume":"17","year":"1999","unstructured":"Cartwright, K., R. Morris, H. R\u00fcmke, A. Fox, R. Borrow, N. Begg, P. Richmond, and J. Poolman. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine17:2612-2619.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/infdis\/137.2.112","volume":"137","year":"1978","unstructured":"Gold, R., I. Goldschneider, M. L. Lepow, T. F. Draper, and M. Randolph. 1978. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis.137:112-121.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_8_2","first-page":"147","volume":"14","year":"1991","unstructured":"H\u00f8iby, E. A., E. Rosenqvist, L. O. Fr\u00f8holm, G. Bjune, B. Feiring, H. N\u00f8kleby, and E. Ronnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann.14:147-156.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. H\u00f8iby, H. N\u00f8kleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","volume":"177","year":"1998","unstructured":"Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177:497-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4419-4424.1994"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","volume":"177","year":"1998","unstructured":"Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A H\u00f8iby, E. Rosenqvist, J. Holst, H. N\u00f8kleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/infdis\/167.5.1065","volume":"167","year":"1993","unstructured":"Rosenqvist, E., E. A. H\u00f8iby, E. Wedege, B. Kusecek, and M. Achtman. 1993. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis.167:1065-1073.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_16_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_17_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. N\u00f8kleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","volume":"21","year":"2003","unstructured":"Trotter, C., R. Borrow, N. Andrews, and E. Miller. 2003. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine21:1094-1098.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.8.970-976.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.8.970-976.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:36:37Z","timestamp":1627590997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.12.8.970-976.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1128\/CDLI.12.8.970-976.2005"],"URL":"https:\/\/doi.org\/10.1128\/cdli.12.8.970-976.2005","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"2005-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}